6-K
Fresenius Medical Care AG (FMS)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
For the month of February 2023
Commission file number: 001-32749
FRESENIUS MEDICAL CARE AG & Co. KGaA
(Translation of registrant's name into English)
Else-Kröner Strasse 1
61346 Bad Homburg
Germany
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
EXHIBITS
The following exhibits are being furnished with this Report:
| Exhibit 99.1 | Ad-hoc statement issued on February 9, 2023. |
|---|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
DATE: February 9, 2023
| Fresenius Medical Care AG & Co. KGaA, a partnership limited by shares, represented by: | |
|---|---|
| fresenius medical care management ag, its General Partner | |
| By: | /s/ Helen Giza |
| --- | --- |
| Name: | Helen Giza |
| Title: | Chief Executive Officer, Chair of the Management Board of the General Partner and Acting Chief Financial Officer |
| By: | /s/ Dr. Katarzyna Mazur-Hofsäß |
| Name: | Dr. Katarzyna Mazur-Hofsäß |
| Title: | CEO Care Enablement and member of the Management Board of the General Partner |
Exhibit 99.1
Ad-hoc announcement according to Art. 17 (1) MAR
February 9^th^, 2023
Fresenius Medical Care AG & Co.KGaA confirms review of the deconsolidation and a potential change of the legal form into a German stock corporation
Following press reports, Fresenius Medical Care AG & Co. KGaA (“Company”) confirms that Fresenius SE & Co. KGaA, which is holding approx. 32% of the shares of the Company and which is the sole shareholder of the general partner Fresenius Medical Care Management AG, is reviewing the deconsolidation of the Company. This review includes a potential change of the legal form of the Company into a German stock corporation (Aktiengesellschaft). The review of the required measures by the Company continues and the necessary decisions of the competent bodies are still outstanding. It therefore remains open whether a deconsolidation and a change of the legal form will occur.
Contact:
Dr. Dominik Heger
EVP | Head of Investor Relations, Strategic Development & Communications
P. +49 6172 609 2601